Genetic variation in inflammatory pathways is related to colorectal cancer survival

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 7139-7147

  Coghill, Anna E ^a   Newcomb, Polly A ^a   Poole, Elizabeth M ^a,b,c   Hutter, Carolyn M ^a   Makar, Karen W ^a   Duggan, Dave ^d   Potter, John D ^a,e   Ulrich, Cornelia M ^a,f  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^e MASSEY UNIVERSITY   (New Zealand)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DEATH; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IKAPPABKBETA GENE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MRP4 GENE; NKKAPPAB GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PTGS 1 GENE; PTGS 2 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VITAL STATISTICS;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSTAGLANDINS; PROTEIN-SERINE-THREONINE KINASES; RISK; SIGNAL TRANSDUCTION;

EID: 81255138176     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1134     Document Type: Article

References (50)

1. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138:2101-14.e5.
2. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40. (Pubitemid 43361545)
3. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006; 13:118-37.
4. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007;19:209-16. (Pubitemid 46356960)
5. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation- mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010;29:243-8.
6. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. (Pubitemid 36297997)
7. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82. (Pubitemid 44958508)
8. Baron JA. Aspirin and NSAIDs for the prevention of colorectal cancer. Recent Results Cancer Res 2009;181:223-9.
9. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
10. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 2011;60: 491-8.
11. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376: 1741-50.
12. Chan TA. Prostaglandins and the colon cancer connection. Trends Mol Med 2006;12:240-4. (Pubitemid 43868157)
13. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, et al. The COX-2/PGE2 pathway: key roles in the hall-marks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30:377-86.
14. Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005;128:1445-61. (Pubitemid 40712194)
15. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004;215:1-20. (Pubitemid 39221453)
16. Buchanan FG, Chang W, Sheng H, Shao J, Morrow JD, DuBois RN. Up-regulation of the enzymes involved in prostacyclin synthesis via Ras induces vascular endothelial growth factor. Gastroenterology 2004;127:1391-400. (Pubitemid 39457766)
17. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-8.
18. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
19. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009;6:327-34.
20. Horst D, Budczies J, Brabletz T, Kirchner T, Hlubek F. Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer 2009;115:4946-58.
21. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5: 749-59. (Pubitemid 41400849)
22. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006;38:1654-61. (Pubitemid 43947653)
23. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006;25:6800-16. (Pubitemid 44657853)
24. Fan Y, Dutta J, Gupta N, Fan G, Gelinas C. Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 2008;615:223-50.
25. Iglesias D, Nejda N, Azcoita MM, Schwartz S Jr, Gonzalez-Aguilera JJ Fernandez-Peralta AM.Effect of COX2 -765G>C and c.3618A>G polymorphisms on the risk and survival of sporadic colorectal cancer. Cancer Causes Control 2009;20:1421-9.
26. Andersen V, Christensen J, Overvad K, Tjonneland A, Vogel U. Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer 2010;10:484.
27. Curtin K, Wolff RK, Herrick JS, Abo R, Slattery ML. Exploring multilocus associations of inflammation genes and colorectal cancer risk using hapConstructor. BMC Med Genet 2010;11:170.
28. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. Polymorphisms in PTGS1 (= COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004;13:889-93. (Pubitemid 38737881)
29. Zhu W, Wei BB, Shan X, Liu P. -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep 2010;37:277-88.
30. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2331-43. (Pubitemid 351196365)
31. Levine AJ, Figueiredo JC, Lee W, Conti DV, Kennedy K, Duggan DJ, et al. A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19:1812-21.
32. Calle EE, Terrell DD. Utility of the National Death Index for ascertainment of mortality among cancer prevention study II participants. Am J Epidemiol 1993;137:235-41. (Pubitemid 23083676)
33. Stampfer M, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index.AmJ Epidemiol 1984;119:837-9. (Pubitemid 14142821)
34. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
35. Benjamini Ya Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodological) 1995;57:289-300.
36. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84. (Pubitemid 33000466)
37. Lee CR, Bottone FG, Jr., Krahn JM, Li L, Mohrenweiser HW, Cook ME, et al. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 2007;17:145-60.
38. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002;20:409-10.
39. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83:324-8. (Pubitemid 30453571)
40. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003;63: 2330-4. (Pubitemid 36538645)
41. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets down-stream of COX-2. Annu Rev Med 2007;58:239-52. (Pubitemid 46706512)
42. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4705-8.
43. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989;259:315-24. (Pubitemid 19111664)
44. Takafuji VA, Evans A, Lynch KR, Roche JK. PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer. Prostaglandins Leukot Essent Fatty Acids 2002;66:71-81. (Pubitemid 34717689)
45. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96. (Pubitemid 39061110)
46. Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 2008;18:334-42. (Pubitemid 351333897)
47. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005;434:1138-43. (Pubitemid 40663493)
48. Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB) - a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev 2008;19:157-65. (Pubitemid 351382281)
49. Tenesa A, Theodoratou E, Din FV, Farrington SM, Cetnarskyj R, Barnetson RA, et al. Ten common genetic variants associated with colorectal cancer risk are not associated with survival after diagnosis. Clin Cancer Res 2010;16:3754-9.
50. van den Oord EJ. Controlling false discoveries in genetic studies. Am J Med Genet B Neuropsychiatr Genet 2008;147B: 637-44.